# Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

> **NCT05412290** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 15 (estimated)

## Conditions studied

- B Cell Lymphoma
- Aggressive Lymphoma
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Lymphoma
- Follicular Lymphoma Grade 3

## Interventions

- **DRUG:** Mosunetuzumab

## Key facts

- **NCT ID:** NCT05412290
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-22
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412290, "Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05412290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*